You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

PTCL-NOS

Showing 26 - 50 of 241
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Peripheral T Cell Lymphoma Trial in Harlingen (Belinostat Injection, Pralatrexate Injection, CHOP)

Not yet recruiting
  • Peripheral T Cell Lymphoma
  • Belinostat Injection
  • +3 more
  • Harlingen, Texas
    Valley Cancer Associates
Oct 16, 2023

A Study of People With CD30 Positive Lymphoma in China

Not yet recruiting
  • Lymphoma
    • (no location specified)
    Aug 17, 2022

    Peripheral T Cell Lymphoma, Relapse/Recurrence Trial in Belgium, France (Lacutamab, Gemcitabine, Oxaliplatine)

    Recruiting
    • Peripheral T Cell Lymphoma
    • Relapse/Recurrence
    • Antwerpen, Belgium
    • +38 more
    Dec 6, 2021

    Peripheral T-Cell Lymphoma, Not Otherwise Specified, Angioimmunoblastic T Cell Lymphoma, ALK-negative Anaplastic Large Cell

    Unknown status
    • Peripheral T-Cell Lymphoma, Not Otherwise Specified
    • +5 more
    • CEOP/IVE/GDP chemotherapy regimen
    • CEOP chemotherapy regimen for 6 cycles
    • Fuzhou, Fujian, China
    • +3 more
    Mar 7, 2020

    Relapsed or Refractory Peripheral T-cell Lymphoma Trial in Taiwan (Chidamide)

    Not yet recruiting
    • Relapsed or Refractory Peripheral T-cell Lymphoma
    • Kaohsiung, Taiwan
    • +4 more
    Apr 17, 2023

    Brentuximab Vedotin Intravenous Infusion "Relapsed or Refractory

    Active, not recruiting
    • Peripheral T Cell Lymphoma
    • Pediatric Hodgkin Lymphoma
    • Brentuximab Vedotin (Genetical Recombination)
    • Tokyo, Japan
      Takeda Selected Site
    Oct 11, 2022

    Peripheral T Cell Lymphoma Trial in Zhengzhou (Golidocitinib, CHOP Regimen)

    Not yet recruiting
    • Peripheral T Cell Lymphoma
    • Zhengzhou, Henan, China
      Henan Cancer Hospital
    Jul 18, 2023

    Peripheral T-Cell Lymphoma (PTCL) Trial in Japan, Korea, Republic of (HBI-8000)

    Completed
    • Peripheral T-Cell Lymphoma (PTCL)
    • Akita, Japan
    • +22 more
    Jun 8, 2022

    Allo-HSCT as First-line Consolidation in High-risk PTCL

    Recruiting
    • T Cell Lymphoma
      • Beijing, China
        Peking University People's Hospital
      Jul 31, 2022

      Peripheral T-cell Lymphoma Trial in Worldwide (brentuximab vedotin, cyclophosphamide, doxorubicin)

      Recruiting
      • Peripheral T-cell Lymphoma
      • brentuximab vedotin
      • +3 more
      • Birmingham, Alabama
      • +45 more
      Jan 4, 2023

      Peripheral T-cell Lymphoma Trial (Linperlisib in combination with CHOP)

      Not yet recruiting
      • Peripheral T-cell Lymphoma
      • Linperlisib in combination with CHOP
      • (no location specified)
      Jul 10, 2023

      T-cell Non-Hodgkin Lymphoma Trial in Boston (Cyclophosphamide, Doxorubicin, Vincristine)

      Terminated
      Has Results
      • T-cell Non-Hodgkin Lymphoma
      • Boston, Massachusetts
      • +1 more
      Jan 26, 2023

      Neurological Recovery Following NOS-SACD

      Not yet recruiting
      • Nitrous Oxide Abuse
      • +4 more
      • Observational study with no interventions
      • (no location specified)
      Feb 2, 2023

      Relapsed/Refractory Peripheral T-cell Lymphoma, Relapsed/Refractory Classical Hodgkins Lymphoma Trial in Worldwide (AZD4573)

      Recruiting
      • Relapsed/Refractory Peripheral T-cell Lymphoma
      • Relapsed/Refractory Classical Hodgkins Lymphoma
      • Duarte, California
      • +33 more
      Jan 5, 2023

      Peripheral T-Cell Lymphoma, Lenalidomide, CHOP Trial in Hangzhou (Lenalidomide, Cyclophosphamide, Doxorubicin)

      Recruiting
      • Peripheral T-Cell Lymphoma
      • +2 more
      • Hangzhou, Zhejiang, China
        2nd Affiliated Hospital, School of Medicine, Zhejiang University
      Nov 3, 2022

      Lymphoma Trial in China (Brentuximab Vedotin, Cyclophosphamide, Doxorubicin)

      Not yet recruiting
      • Lymphoma
      • Brentuximab Vedotin
      • +3 more
      • Beijing, China
      • +15 more
      Jan 4, 2023

      Circulating Tumor DNA Sequencing in Peripheral T-cell Lymphomas

      Not yet recruiting
      • Peripheral T Cell Lymphoma
      • circulating tumoral DNA detection
      • Rouen, France
        Centre Henri Becquerel
      Oct 13, 2023

      Relapsed or Refractory Hodgkin Lymphoma, Peripheral T Cell Lymphoma Trial (AFM13, AB-101, Cyclophosphamide)

      Not yet recruiting
      • Relapsed or Refractory Hodgkin Lymphoma
      • Peripheral T Cell Lymphoma
      • (no location specified)
      May 30, 2023

      Smoking, Cigarette, Smoking E-cigarette, Healthy Volunteer Trial in Philadelphia ([18F]NOS)

      Recruiting
      • Smoking, Cigarette
      • +2 more
      • Philadelphia, Pennsylvania
        University of Pennsylvania
      Jan 19, 2023

      Peripheral T Cell Lymphoma Trial (CHOP+selinexor+5-Azacitidine, CHOP+duvelisib+5-Azacitidine, CHOP+chidamide+tislelizumab)

      Not yet recruiting
      • Peripheral T Cell Lymphoma
      • (no location specified)
      Dec 29, 2022

      Peripheral T Cell Lymphoma Trial in Beijing (Linperlisib in combined with Chidamide)

      Recruiting
      • Peripheral T Cell Lymphoma
      • Linperlisib in combined with Chidamide
      • Beijing, Beijing/China, China
      • +1 more
      Oct 9, 2023

      Newly Diagnosed Peripheral T-cell Lymphoma Trial in Nanjing (C-BEAM Regimen, BEAM Regimen)

      Recruiting
      • Newly Diagnosed Peripheral T-cell Lymphoma
      • C-BEAM Regimen
      • BEAM Regimen
      • Nanjing, Jiangsu, China
        Hematological Department, People's Hospital of Jiangsu Province
      Jun 27, 2023

      Irritable Bowel Syndrome, Functional Abdominal Pain Syndrome, Child Trial in Almere, Breda, Amsterdam (Small intestinal release

      Recruiting
      • Irritable Bowel Syndrome
      • +5 more
      • Small intestinal release peppermint oil
      • +2 more
      • Almere, Flevoland, Netherlands
      • +2 more
      Mar 22, 2023

      Previously Untreated Peripheral T-cell Lymphoma Trial in Tampa, Saint Louis, New York (CC-486 Administration, CHOP

      Active, not recruiting
      Has Results
      • Previously Untreated Peripheral T-cell Lymphoma
      • CC-486 Administration
      • CHOP Administration
      • Tampa, Florida
      • +3 more
      Jan 18, 2023

      Peripheral T-cell Lymphoma Trial in Worldwide (Romidepsin + CHOP, CHOP)

      Completed
      • Peripheral T-cell Lymphoma
      • Antwerpen, Belgium
      • +130 more
      Jan 9, 2023